COVID-19 Vaccine Program
Developing potent, broadly protective vaccines against this pandemic virus.
PDS Biotech is proud to respond to the continuing COVID-19 global health emergency. This page summarizes our work to advance PDS0203 and PDS0204, our vaccine candidates against the novel coronavirus. Both PDS0203 and PDS0204 stimulate a broad, potent and rapid immune response using the Versamune® platform that is simple, safe and scaleable.
COVID-19 vaccines that rapidly produces both T-cells and antibodies against SARS-CoV-2
Versamune®-based vaccines are designed to train the immune system to better protect against infectious diseases. Versamune® delivers both a protective antibody and powerful T-cell response with minimal side effects. Versamune® also induces long-term memory T-cell responses. T-cells are an essential component of our immune system with the unique ability to attack foreign agents, including viruses. The advantage of inducing virus-specific T-cell responses in addition to neutralizing antibodies is that it provides broader protection against severe illness caused by viruses like SARS-CoV-2, the virus responsible for COVID-19. The advantage of inducing virus-recognizing memory T-cell responses is that this protection may be retained for several years.
PDS Biotech has demonstrated that our Versamune® platform safely produces a robust T-cell response against viral targets in humans. Our goal for both PDS0203 and PDS0204 – each of which contains a different antigen of SARS-CoV-2 - is to demonstrate rapid immune responses after a single vaccine dose that is well tolerated.